In vitro methods for inhibiting HHV-6 infection
By contacting immune cells with antiviral agents during cell culture, preventing and controlling the replication and reactivated of HHV-6, the risk of foreign viral infection in cell-based therapies is solved, ensuring the safety and productivity of the drug.
Patent Information
- Application Number
- CN202380059828.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-23
- Filing Date
- 2023-08-16
- Publication Date
- 2025-03-28
AI Technical Summary
In the manufacturing of cell-based therapies, rare events of infection after exotic viral infection or reactivated need to be prevented and controlled to ensure drug safety and minimize waste. Meanwhile, the lack of cell culture models of latent HHV-6 infection and reactivation hinders research in this field.
A method is provided for preventing, controlling or inhibiting HHV-6 replication by contacting immune cells with an antiviral agent in the culture medium after reactivated immune cells. The method involves the use of antiviral agents such as interferons (such as IFNα), ganciclovir, cidofovir or foscaric acid and adding them to the medium for a specific time period.
Through this method, the risk of HHV-6 replication or infection after HHV-6 replication, transcriptional activation, infection or reactivated can be significantly reduced, ensuring the safety of the drug and reducing waste.